Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Belimumab by GSK for Graft Versus Host Disease (GVHD): Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase I for Graft Versus Host Disease (GVHD). According to...
Belimumab by GSK for Cryoglobulinemia: Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase II for Cryoglobulinemia. According to GlobalData, Phase II drugs...
Belimumab by GSK for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase III for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)....
Belimumab by GSK for Rheumatoid Arthritis: Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase III for Rheumatoid Arthritis. According to GlobalData, Phase III...
Belimumab by GSK for Graves Diseases: Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase II for Graves Diseases. According to GlobalData, Phase II...